Clinical trials: Advanced Solid Malignant Tumors
Advanced Solid Tumors
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
- Trial name
- NCT05172856
- Testing
- IBI321
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumors
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation study of the study drug YH001 . The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 in subjects with…
- Trial name
- NCT04699929
- Testing
- YH001
- Where
- 3 sites in China
- Volunteers
- 17 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Solid Tumors, Non-small Cell Lung Carcinoma
A Study of DS-2248 in Participants With Advanced Solid Tumors
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors.
- Trial name
- NCT01288430
- Testing
- DS-2248
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors, Lymphoma
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .
- Trial name
- NCT03733951
- Testing
- KN046
- Where
- 13 sites in China
- Volunteers
- 139 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Advanced Malignant Solid Tumors
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
- Trial name
- NCT07806175
- Testing
- RCZY690 Tablets, RCZY690 tables
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- Rongchang Pharmaceuticals Co., Ltd.
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Advanced Solid Tumors
Study of the AL3810 in the Treatment of Advanced Solid Tumor
This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
- Trial name
- NCT03117101
- Testing
- Lucitanib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Neoplasms
A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor
Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular Endothelial Growth Factor Receptor (VEGFR). This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and preliminary…
- Trial name
- NCT02717741
- Testing
- tafetinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Neoplasms
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
Study to determine the maximum tolerated dose (MTD) for various treatment durations of BIBW 2992 when administered in combination with docetaxel as determined by drug-related adverse events (AEs) as well as Pharmacokinetics…
- Trial name
- NCT02171741
- Testing
- BIBW 2992, Docetaxel
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase.
- Trial name
- NCT03991494
- Testing
- [14C]-pamiparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- BeiGene
Breast Cancer, Solid Tumor
A Study of TY-302 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: TY-302 Tamoxifen
- Trial name
- NCT04433494
- Testing
- TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- TYK Medicines, Inc
Neoplasms
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors.
- Trial name
- NCT04635631
- Testing
- talazoparib
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Pfizer
Metastatic or Locally Advanced Unresectable Solid Tumors
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and…
- Trial name
- NCT04170153
- Testing
- M1774, Niraparib
- Where
- 16 sites in United States, China and 3 more
- Volunteers
- 161 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with…
- Trial name
- NCT00591383
- Testing
- indibulin, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alaunos Therapeutics
Solid Tumors
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors.
- Trial name
- NCT01415297
- Testing
- NKP-1339
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Niiki Pharma Inc.
Tumors
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
This is a Phase 1, open-label, randomized, 2-sequence, cross-over, pharmacokinetic (PK) study evaluating the effect of the DPD inhibitory action of CDHP as an S-1 component compared with FT alone on the PK of 5-FU in patients…
- Trial name
- NCT00400023
- Testing
- S-1, FT
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors, Lymphoma
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
- Trial name
- NCT01953783
- Testing
- IXAZOMIB
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.